Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma.
暂无分享,去创建一个
M. Loda | M. Fiorentino | A. Altimari | A. D’Errico | B. Cukor | C. Barozzi | W. Grigioni | A. d’Errico | Antonia D'errico | Michelangelo Fiorentino | Barry Cukor | Massimo Loda
[1] J. Albrecht,et al. Regulation of G1 cyclin-dependent kinases in the liver: role of nuclear localization and p27 sequestration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[2] G. Viglietto,et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. , 1999, The Journal of clinical investigation.
[3] M. Monden,et al. Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.
[4] R. Agarwal,et al. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[5] G. Firestone,et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. , 1999, Cancer research.
[6] J. Albrecht,et al. Regulation of G 1 cyclin-dependent kinases in the liver : role of nuclear localization and p 27 sequestration , 1999 .
[7] C. Cordon-Cardo,et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.
[8] James M. Roberts,et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.
[9] C. Sherr,et al. Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.
[10] M. Loda,et al. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. , 1998, The American journal of pathology.
[11] M. Kitagawa,et al. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. , 1998, The American journal of pathology.
[12] H. Miyake,et al. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] J. Albrecht,et al. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver , 1998, Oncogene.
[14] M. Loda,et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.
[15] Jeng-Jong Hwang,et al. Ki‐67 expression as a prognostic marker in patients with hepatocellular carcinoma , 1998, Journal of gastroenterology and hepatology.
[16] C. Saccone,et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. , 1998, British Journal of Cancer.
[17] L. Klotz,et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.
[18] A. Puisieux,et al. Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[19] N. Toyota,et al. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. , 1998, Anticancer research.
[20] G. Cattoretti,et al. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.
[21] N. Nishida,et al. Alteration of cell cycle-related genes in hepatocarcinogenesis. , 1997, Histology and histopathology.
[22] Esposito,et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.
[23] K. Mimori,et al. p27 expression and gastric carcinoma , 1997, Nature Medicine.
[24] M. Loda,et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.
[25] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[26] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[27] Herman Yeger,et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.
[28] C. Sherr. Cancer Cell Cycles , 1996, Science.
[29] Philip D. Jeffrey,et al. Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.
[30] Nobuyuki Shishido,et al. Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.
[31] James M. Roberts,et al. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.
[32] K. Manova-Todorova,et al. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.
[33] H. Koeffler,et al. p27/Kipl Mutation Found in Breast Cancer1 , 1996 .
[34] M. Loda,et al. Cell cycle and cancer: critical events at the G1 restriction point. , 1996, Critical reviews in oncogenesis.
[35] P. Beer-Romero,et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.
[36] C. Bartram,et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.
[37] D N Shapiro,et al. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4 , 1995, Molecular and cellular biology.
[38] M. Roussel,et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.
[39] J. Massagué,et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.
[40] James M. Roberts,et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.
[41] M. Colombo,et al. Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.
[42] James M. Roberts,et al. Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.
[43] L. Hengst,et al. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells , 1994, Molecular and cellular biology.
[44] A. Nakao,et al. Hepatic resection for hepatocellular carcinoma. , 1997, American journal of surgery.
[45] H. Koyama,et al. Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. , 1992, Surgery.
[46] S. Arii,et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy , 1992, Cancer.
[47] F. Miglio,et al. [Epidemiology of hepatocellular carcinoma]. , 1991, Minerva gastroenterologica e dietologica.
[48] R. Peters,et al. Tumors of the Liver and Intrahepatic Bile Ducts , 1990 .
[49] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.